CY1114808T1 - Μεθοδος επιλογης πεπτιδιου - Google Patents

Μεθοδος επιλογης πεπτιδιου

Info

Publication number
CY1114808T1
CY1114808T1 CY20131101143T CY131101143T CY1114808T1 CY 1114808 T1 CY1114808 T1 CY 1114808T1 CY 20131101143 T CY20131101143 T CY 20131101143T CY 131101143 T CY131101143 T CY 131101143T CY 1114808 T1 CY1114808 T1 CY 1114808T1
Authority
CY
Cyprus
Prior art keywords
selection method
peptide
peptide selection
selecting
disease
Prior art date
Application number
CY20131101143T
Other languages
English (en)
Inventor
David Cameron Wraith
Stephen Mark Anderton
Graziella Mazza
Mary Ponsford
Heather Barbara Streeter
Original Assignee
Apitope Technology (Bristol) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114808(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0020618A external-priority patent/GB0020618D0/en
Priority claimed from GB0114547A external-priority patent/GB0114547D0/en
Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited
Publication of CY1114808T1 publication Critical patent/CY1114808T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Παρέχεται μια μέθοδος για την επιλογή ενός επαγωγικού ανοχής πεπτιδίου, μέσω της επιλογής ενός πεπτιδίου, το οποίο είναι ικανό να δεσμεύεται σε ένα μόριο MHC τάξεως Ι ή ΙΙ, χωρίς περαιτέρω επεξεργασία. Παρέχεται επίσης ένα πεπτίδιο που επιλέγεται από μια τέτοια μέθοδο και την χρήση της σε μια φαρμακευτική σύνθεση και μια μέθοδος για την αγωγή και/ή πρόληψη μιας ασθένειας.
CY20131101143T 2000-08-21 2013-12-18 Μεθοδος επιλογης πεπτιδιου CY1114808T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020618A GB0020618D0 (en) 2000-08-21 2000-08-21 Peptide selection method
GB0114547A GB0114547D0 (en) 2001-06-14 2001-06-14 Peptide selection method
EP06014901.0A EP1731912B1 (en) 2000-08-21 2001-08-17 Peptide selection method

Publications (1)

Publication Number Publication Date
CY1114808T1 true CY1114808T1 (el) 2016-12-14

Family

ID=26244875

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081101132T CY1108558T1 (el) 2000-08-21 2008-10-13 Πεπτιδια επαγωγικα ανοχης
CY20111100017T CY1111079T1 (el) 2000-08-21 2011-01-04 Πεπτιδιο
CY20131101143T CY1114808T1 (el) 2000-08-21 2013-12-18 Μεθοδος επιλογης πεπτιδιου

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20081101132T CY1108558T1 (el) 2000-08-21 2008-10-13 Πεπτιδια επαγωγικα ανοχης
CY20111100017T CY1111079T1 (el) 2000-08-21 2011-01-04 Πεπτιδιο

Country Status (25)

Country Link
US (4) US20030191063A1 (el)
EP (3) EP1918298B1 (el)
JP (1) JP5431628B2 (el)
KR (1) KR20030062321A (el)
CN (4) CN102784385B (el)
AT (2) ATE401343T1 (el)
AU (2) AU2001278637B2 (el)
BR (2) BR0113400A (el)
CA (1) CA2420949C (el)
CY (3) CY1108558T1 (el)
CZ (1) CZ307202B6 (el)
DE (2) DE60143234D1 (el)
DK (3) DK1731912T3 (el)
ES (3) ES2310558T3 (el)
HK (3) HK1052359B (el)
HU (3) HU229377B1 (el)
IL (1) IL154089A0 (el)
MX (1) MXPA03001606A (el)
NO (2) NO330535B1 (el)
NZ (1) NZ523841A (el)
PH (1) PH12013500208A1 (el)
PL (4) PL215145B1 (el)
PT (3) PT1918298E (el)
SI (3) SI1918298T1 (el)
WO (1) WO2002016410A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1918298T1 (sl) 2000-08-21 2011-01-31 Apitope Technology Bristol Ltd Peptid
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
PL2420833T3 (pl) * 2006-05-05 2016-03-31 Opexa Therapeutics Szczepionka z komórek T
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PT2083856E (pt) 2007-08-15 2010-12-23 Circassia Ltd Péptidos para a dessensibilização contra alergénios
SI2211892T1 (sl) * 2007-10-31 2011-12-30 Apitope Technology Bristol Ltd Sestavki, ki obsegajo peptide mielinskega bazičnega proteina in njihove medicinske uporabe
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
ITMI20080508A1 (it) * 2008-03-27 2009-09-28 Istituto Nazionale Di Genetica Molecolare Cellule ematopoietiche esprimenti la proteina krtcap3 e i leganti per la proteina krtcap3
ITMI20080865A1 (it) * 2008-05-13 2009-11-14 Istituto Naz Di Genetica Molecolare Ingm Cellule ematopoietiche esprimenti la proteina susd3 e i leganti per la proteina susd3
WO2010127186A1 (en) 2009-04-30 2010-11-04 Prognosys Biosciences, Inc. Nucleic acid constructs and methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
AU2009354040A1 (en) 2009-10-12 2012-05-31 Lifebio Laboratories Llc Composition for treatment of Multiple Sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
CA2794522C (en) 2010-04-05 2019-11-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
KR200457779Y1 (ko) * 2010-06-23 2012-01-06 이준혁 샤프펜슬
US20120258871A1 (en) 2011-04-08 2012-10-11 Prognosys Biosciences, Inc. Peptide constructs and assay systems
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
PL397623A1 (pl) * 2011-12-30 2013-07-08 Napco S. Ar.L. Preparat poprawiajacy pamiec oraz uczenie sie, sposób jego wytwarzania, srodek farmaceutyczny, dodatek zywieniowy oraz jego zastosowanie
CA2890835C (en) 2012-11-12 2021-11-23 Apitope Technology (Bristol) Limited Factor viii-derived peptides for use in the treatment of haemophilia a
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
WO2014145047A1 (en) * 2013-03-15 2014-09-18 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
EP3013984B1 (en) 2013-06-25 2023-03-22 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
WO2015070037A2 (en) 2013-11-08 2015-05-14 Prognosys Biosciences, Inc. Polynucleotide conjugates and methods for analyte detection
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2016103213A1 (en) * 2014-12-24 2016-06-30 Apitope International Nv Composition
EP3530752B1 (en) 2015-04-10 2021-03-24 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
JP7174492B2 (ja) * 2017-01-04 2022-11-17 ウォルグ ファーマシューティカルズ （ハンジョウ） カンパニー，リミテッド Ｓ－アレスチンペプチドおよびその治療的使用
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
WO2018127828A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv Therapeutic method using tolerogenic peptides
BR112019007714B1 (pt) 2017-01-06 2022-01-18 Eutilex Co., Ltd Anticorpos anti-4-1bb, uso do mesmo, composição farmacêutica, métodos para determinar uma dose, para aumentar a secreção de ifn-gama por uma célula in vitro e para proliferação ex vivo ou isolamento de células t ativadas e uso das mesmas
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method
RU2761617C2 (ru) * 2019-10-04 2021-12-13 Жаудат Гафурович Умеров Комплекс липидов миелина центральной и периферической нервной системы животных для лечения и профилактики нейродегенеративных демиелинизирующих нарушений и способы его применения
GB201919222D0 (en) 2019-12-23 2020-02-05 Apitope Int Nv Composition
TR201922305A2 (tr) * 2019-12-30 2021-07-26 T C Erciyes Ueniversitesi Multi̇pl skleroz (ms) hastaliğinda beta-kazomorfi̇n pepti̇tleri̇ni̇n kullanilmasi
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
AU2021208602A1 (en) 2020-05-06 2022-12-15 Imcyse Sa Combination treatment for fumarate-related diseases
EP4153775A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327162C (en) 1987-04-09 1994-02-22 Board Of Trustees Of The Leland Stanford Junior University (The) Method for prophylactically treating an individual for an autoimmune disease
EP0666080B1 (en) 1987-06-24 2004-01-21 Brigham & Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US6077509A (en) * 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
US5593698A (en) * 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5989565A (en) * 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
CZ329596A3 (en) * 1994-05-10 1997-05-14 Immulogic Pharma Corp Preparation for treating scattered sclerosis
WO1995031997A1 (en) 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Model for testing immunogenicity of peptides
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) * 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
CA2216936A1 (en) * 1995-04-20 1996-10-24 Howard L. Weiner Modulation of cytokine patterns of human autoreactive t-cell clones
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
EP0849275A1 (en) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
WO1999063945A2 (en) 1998-06-12 1999-12-16 Sloan-Kettering Institute For Cancer Research Vaccination strategy to prevent and treat cancers
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
SI1918298T1 (sl) * 2000-08-21 2011-01-31 Apitope Technology Bristol Ltd Peptid
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
US8314290B2 (en) 2004-12-21 2012-11-20 Monsanto Technology Llc Temporal regulation of gene expression by MicroRNAs
SI2211892T1 (sl) * 2007-10-31 2011-12-30 Apitope Technology Bristol Ltd Sestavki, ki obsegajo peptide mielinskega bazičnega proteina in njihove medicinske uporabe
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides

Also Published As

Publication number Publication date
SI1731912T1 (sl) 2014-05-30
US20030191063A1 (en) 2003-10-09
ES2353347T3 (es) 2011-03-01
ES2439899T3 (es) 2014-01-27
NO337988B1 (no) 2016-07-18
PH12013500208B1 (en) 2015-04-20
HK1052359B (zh) 2008-11-14
HU230233B1 (hu) 2015-10-28
CN102764425B (zh) 2015-11-25
WO2002016410A3 (en) 2002-09-12
ATE483729T1 (de) 2010-10-15
CN102784385A (zh) 2012-11-21
PL364048A1 (en) 2004-12-13
JP5431628B2 (ja) 2014-03-05
CA2420949C (en) 2012-01-03
US8961986B2 (en) 2015-02-24
PT1918298E (pt) 2010-12-09
EP1311542A2 (en) 2003-05-21
CY1108558T1 (el) 2014-04-09
EP1918298B1 (en) 2010-10-06
JP2004506921A (ja) 2004-03-04
HUP0300814A2 (hu) 2003-10-28
PH12013500208A1 (en) 2015-04-20
IL154089A0 (en) 2003-07-31
NO330535B1 (no) 2011-05-09
EP1918298A2 (en) 2008-05-07
CY1111079T1 (el) 2015-06-11
HK1178793A1 (en) 2013-09-19
HK1052359A1 (en) 2003-09-11
US20080200368A1 (en) 2008-08-21
PL399137A1 (pl) 2012-07-30
SI1918298T1 (sl) 2011-01-31
NO20030790L (no) 2003-04-22
CN102784385B (zh) 2015-11-25
HU229489B1 (hu) 2014-01-28
PL213585B1 (pl) 2013-03-29
EP1311542B1 (en) 2008-07-16
AU2001278637B2 (en) 2006-05-25
CZ307202B6 (cs) 2018-03-21
DE60143234D1 (de) 2010-11-18
AU7863701A (en) 2002-03-04
DE60134862D1 (de) 2008-08-28
CA2420949A1 (en) 2002-02-28
NZ523841A (en) 2004-07-30
BR0113400A (pt) 2003-07-08
EP1731912B1 (en) 2013-09-25
SI1311542T1 (sl) 2009-02-28
HU229377B1 (hu) 2013-11-28
HK1178437A1 (en) 2013-09-13
US20130156798A1 (en) 2013-06-20
DK1918298T3 (da) 2010-11-29
WO2002016410A2 (en) 2002-02-28
CN102764425A (zh) 2012-11-07
PT1311542E (pt) 2008-10-03
PT1731912E (pt) 2013-12-17
NO20030790D0 (no) 2003-02-19
BRPI0113400B1 (pt) 2018-05-15
EP1731912A2 (en) 2006-12-13
CN101633689B (zh) 2013-09-04
ATE401343T1 (de) 2008-08-15
DK1731912T3 (da) 2014-01-06
CN101633689A (zh) 2010-01-27
CN1469883A (zh) 2004-01-21
PL215187B1 (pl) 2013-11-29
PL399138A1 (pl) 2012-07-30
MXPA03001606A (es) 2004-11-01
US8343500B2 (en) 2013-01-01
US20180311328A1 (en) 2018-11-01
PL217929B1 (pl) 2014-09-30
NO20101441L (no) 2003-04-22
EP1731912A3 (en) 2006-12-27
HUP0300814A3 (en) 2005-11-28
ES2310558T3 (es) 2009-01-16
DK1311542T3 (da) 2008-11-10
EP1918298A3 (en) 2008-05-28
KR20030062321A (ko) 2003-07-23
PL215145B1 (pl) 2013-10-31

Similar Documents

Publication Publication Date Title
CY1114808T1 (el) Μεθοδος επιλογης πεπτιδιου
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1122686T1 (el) Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
CY1109730T1 (el) Μιμητικα θρομβοποιητινης
ATE255906T1 (de) Antikörper gegen cd40
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
DK1261377T3 (da) Immunmodulatoriske formuleringer og fremgangsmåder til anvendelse af disse
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DK1503794T3 (da) Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
EA200201214A1 (ru) Замещенные тиоацетамиды
DK1401458T3 (da) Sammensætning bestående af PHY906 og kemoterapeutiske midler
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos